How an untested drugs scandal could lead to better clinical practice
Tuesday, October 18, 2016 - 09:44
in Health & Medicine
Cancer researchers and patients from all over the world can learn valuable lessons from a recent Brazilian scientific scandal, according to a new policy paper. In Brazil, the distribution by "researchers" to patients of an untested compound called phosphoethanolamine (PHOS) led to a widely publicized scientific debacle.